A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults

被引:9
作者
Leroux-Roels, Geert [1 ,2 ]
Lattanzi, Maria [3 ]
Solis, Claudia Dovali [3 ]
Contorni, Mario [3 ]
Costantini, Marco [3 ]
Moraschini, Luca [3 ]
Bardelli, Monia [3 ]
Bertholet, Sylvie [3 ]
Borgogni, Erica [3 ]
Buricchi, Francesca [3 ]
Cantisani, Rocco [3 ]
Faenzi, Elisa [3 ]
Finco, Oretta [3 ]
Leuzzi, Rosanna [3 ]
Pizza, Mariagrazia [3 ]
Rosa, Domenico [3 ]
Schiavetti, Francesca [3 ]
Seubert, Anja [3 ]
Spensieri, Fabiana [3 ]
Volpini, Gianfranco [3 ]
Zedda, Luisanna [3 ]
Del Giudice, Giuseppe [3 ]
Galgani, Ilaria [3 ]
机构
[1] Univ Ghent, Ctr Vaccinol, Ghent, Belgium
[2] Univ Hosp, Ghent, Belgium
[3] GSK, Vaccines, Siena, Italy
关键词
adults; genetically detoxified PT; immunogenicity; persistence; pertussis; safety; UNITED-STATES; WHOLE-CELL; IMMUNIZATION; PERSISTENCE; IMMUNITY; INFANTS; ADOLESCENTS; VACCINATION; PROTECTION; INDUCTION;
D O I
10.1080/21645515.2017.1385686
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Despite high vaccination coverage worldwide, pertussis has re-emerged in many countries. This randomized, controlled, observer-blind phase I study and extension study in Belgium (March 2012-June 2015) assessed safety and immunogenicity of investigational acellular pertussis vaccines containing genetically detoxified pertussis toxin (PT) (NCT01529645; NCT02382913).420 healthy adults (average age: 26.8 5.5years, 60% female) were randomized to 1 of 10 vaccine groups: 3 investigational aP vaccines (containing pertussis antigens PT, filamentous hemagglutinin [FHA] and pertactin [PRN] at different dosages), 6 investigational TdaP (additionally containing tetanus toxoid [TT] and diphtheria toxoid [DT]), and 1 TdaP comparator containing chemically inactivated PT. Antibody responses were evaluated on days 1, 8, 30, 180, 365, and approximately 3years post-booster vaccination. Cell-mediated immune responses and PT neutralization were evaluated in a subset of participants in pre-selected groups. Local and systemic adverse events (AEs), and unsolicited AEs were collected through day 7 and 30, respectively; serious AEs and AEs leading to study withdrawal were collected through day 365 post-vaccination.Antibody responses against pertussis antigens peaked at day 30 post-vaccination and then declined but remained above baseline level at approximately 3years post-vaccination. Responses to FHA and PRN were correlated to antigen dose. Antibody responses specific to PT, toxin neutralization activity and persistence induced by investigational formulations were similar or significantly higher than the licensed vaccine, despite lower PT doses. Of 15 serious AEs, none were considered vaccination-related; 1 led to study withdrawal (premature labor, day 364; aP4 group).This study confirmed the potential benefits of genetically detoxified PT antigen. All investigational study formulations were well tolerated.
引用
收藏
页码:45 / 58
页数:14
相关论文
共 40 条
  • [1] Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1424
  • [2] [Anonymous], PERT WHOOP COUGH SUR
  • [3] Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines
    Ausiello, CM
    Urbani, F
    laSala, A
    Lande, R
    Cassone, A
    [J]. INFECTION AND IMMUNITY, 1997, 65 (06) : 2168 - 2174
  • [4] Infant pertussis - Who was the source?
    Bisgard, KM
    Pascual, FB
    Ehresmann, KR
    Miller, CA
    Cianfrini, C
    Jennings, CE
    Rebmann, CA
    Gabel, J
    Schauer, SL
    Lett, SM
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (11) : 985 - 989
  • [5] Global, regional, and national causes of child mortality in 2008: a systematic analysis
    Black, Robert E.
    Cousens, Simon
    Johnson, Hope L.
    Lawn, Joy E.
    Rudan, Igor
    Bassani, Diego G.
    Jha, Prabhat
    Campbell, Harry
    Walker, Christa Fischer
    Cibulskis, Richard
    Eisele, Thomas
    Liu, Li
    Mathers, Colin
    [J]. LANCET, 2010, 375 (9730) : 1969 - 1987
  • [6] Centers for Disease Control and Prevention, PERT WHOOP COUGH COM
  • [7] Pertussis re-emergence in the post-vaccination era
    Chiappini, Elena
    Stival, Alessia
    Galli, Luisa
    de Martino, Maurizio
    [J]. BMC INFECTIOUS DISEASES, 2013, 13
  • [8] Changing Pertussis Epidemiology: Everything Old is New Again
    Clark, Thomas A.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (07) : 978 - 981
  • [9] Pertussis hospitalizations among infants in the United States, 1993 to 2004
    Cortese, Margaret M.
    Baughman, Andrew L.
    Zhang, Rongping
    Srivastava, Pamela U.
    Wallace, Gregory S.
    [J]. PEDIATRICS, 2008, 121 (03) : 484 - 492
  • [10] Pertussis Disease Burden in the Household: How to Protect Young Infants
    de Greeff, S. C.
    Mooi, F. R.
    Westerhof, A.
    Verbakel, J. M. M.
    Peeters, M. F.
    Heuvelman, C. J.
    Notermans, D. W.
    Elvers, L. H.
    Schellekens, J. F. P.
    de Melker, H. E.
    [J]. CLINICAL INFECTIOUS DISEASES, 2010, 50 (10) : 1339 - 1345